000			01850 a2200469 4500
005			20250517231550.0
264		0	_c20190128
008			201901s 0 0 eng d
022			_a1432-0428
024	7		_a10.1007/s00125-018-4702-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aSattar, Naveed
245	0	0	_aEmpagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. _h[electronic resource]
260			_bDiabetologia _c10 2018
300			_a2155-2163 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdipose Tissue _xmetabolism
650	0	4	_aAsian People
650	0	4	_aAspartate Aminotransferases _xmetabolism
650	0	4	_aBenzhydryl Compounds _xtherapeutic use
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aFemale
650	0	4	_aGlucosides _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xtherapeutic use
650	0	4	_aLiver _xdrug effects
650	0	4	_aMale
650	0	4	_aNon-alcoholic Fatty Liver Disease _xmetabolism
650	0	4	_aResearch Design
650	0	4	_aSodium-Glucose Transporter 2 _xmetabolism
650	0	4	_aSodium-Glucose Transporter 2 Inhibitors _xtherapeutic use
650	0	4	_aSulfonylurea Compounds _xtherapeutic use
650	0	4	_aTime Factors
650	0	4	_aTransaminases _xmetabolism
650	0	4	_aTreatment Outcome
700	1		_aFitchett, David
700	1		_aHantel, Stefan
700	1		_aGeorge, Jyothis T
700	1		_aZinman, Bernard
773	0		_tDiabetologia _gvol. 61 _gno. 10 _gp. 2155-2163
856	4	0	_uhttps://doi.org/10.1007/s00125-018-4702-3 _zAvailable from publisher's website
999			_c28689205 _d28689205